Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Bleeding Prevention in Massive Bone Tumour Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years and older~* Musculoskeletal tumor (primary or metastatic, benign or malignant) located in extremities, shoulder girdle or pelvis.~* Massive or bloc tumour resection.~* Patient's consent to participate~Exclusion Criteria:~* Known allergy to ATX~* Allergy or known hypersensitivity to bovine proteins (aprotinin)~* Liposarcomas low grade~* History of thromboembolic disease or prothrombotic conditions:~  * cerebral vascular accident~ * ischemic heart disease~ * deep and / or superficial vein thrombosis~ * pulmonary embolism~ * peripheral arterial vasculopathy~ * thrombogenic arrhythmias (eg: ACxFA)~ * patients with cardiovascular stents~ * prothrombotic alterations in coagulation~* Treatment with contraceptive drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tranexamic acid (Type: EXPERIMENTAL): Tranexamic acid, 1g intra-articular before closing the surgery wound
- Fibrin glue (Type: EXPERIMENTAL): One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery
- Usual hemostasia (Type: ACTIVE_COMPARATOR): Electrocauterization

Based on this trial design, predict the completion outcome and termination type (if applicable).